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previous studies in model eukaryotes have demonstrated that phosphorylation of heterochromatin 
protein 1 (HP1) is important for dynamically regulating its various functions. However, in the malaria 
parasite Plasmodium falciparum both the function of HP1 phosphorylation and the identity of the 
protein kinases targeting HP1 are still elusive. In order to functionally analyze phosphorylation of 
P. falciparum HP1 (PfHP1), we first mapped PfHP1 phosphorylation sites by liquid chromatography 
tandem mass spectrometry (LC-MS/MS) analysis of native PfHP1, which identified motifs from which 
potential kinases could be predicted; in particular, several phosphorylated residues were embedded 
in motifs rich in acidic residues, reminiscent of targets for P. falciparum casein kinase 2 (PfCK2). 
Secondly, we tested recombinant PfCK2 and a number of additional protein kinases for their ability to 
phosphorylate PfHP1 in in vitro kinase assays. These experiments validated our prediction that PfHP1 
acts as a substrate for PfCK2. Furthermore, LC-MS/MS analysis showed that PfCK2 phosphorylates 
three clustered serine residues in an acidic motif within the central hinge region of PfHP1. To study 
the role of PfHP1 phosphorylation in live parasites we used CRISPR/Cas9-mediated genome editing 
to generate a number of conditional PfHP1 phosphomutants based on the DiCre/LoxP system. Our 
studies revealed that neither PfCK2-dependent phosphorylation of PfHP1, nor phosphorylation of 
the hinge domain in general, affect PfHP1′s ability to localize to heterochromatin, and that PfHP1 
phosphorylation in this region is dispensable for the proliferation of P. falciparum blood stage parasites.
Euchromatin and heterochromatin are the two main structures of chromatin in eukaryotes. While euchroma-
tin is associated with active gene transcription, heterochromatin is associated with heritable gene silencing. 
Heterochromatin is characterized by the enrichment of heterochromatin protein 1 (HP1) bound to trimethylated 
histone 3 lysine 9 (H3K9me3)1–3. HP1 recruits chromatin modifiers such as H3K9me-specific histone methyl-
transferases, which in turn methylate H3K9 in neighbouring nucleosomes, thus facilitating the binding of further 
HP1 proteins and consequently the regional spreading of heterochromatin in a sequence-independent manner3,4. 
In addition to promoting gene silencing and heterochromatin maintenance HP1 also plays roles in centromere 
function in fission yeast and humans and in DNA replication and repair5,6.
HP1 is widely conserved among eukaryotes and consists of three functional domains, namely the N-terminal 
chromo domain (CD) that binds H3K9me31,7,8, the C-terminal chromoshadow domain (CSD) that mediates HP1 
homodimerisation and specific interactions with other regulatory proteins9–11, and a variable hinge region located 
between the CD and CSD domains that has been shown to interact with DNA and/or RNA12–14. Some eukaryotes 
have several HP1 paralogs; for instance, Schizosaccharomyces pombe encodes two HP1 variants (Swi6 and Chp2) 
and mammals possess three HP1 variants (HP1α, HP1β and HP1γ)3,5.
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The parasitic protist Plasmodium falciparum, the causative agent of the most severe form of malaria in 
humans, possesses a single HP1 ortholog (PfHP1). PfHP1 binds to and co-localizes with H3K9me3 to hetero-
chromatic domains in the subtelomeric regions of all 14 chromosomes and to internal heterochromatic islands on 
some chromosomes15–19. There is no evidence for the presence of either PfHP1 or H3K9me3 in peri-centromeric 
regions, suggesting that PfHP1 does not contribute to the maintenance of centromere structure and function in 
this organism15–18,20. The subtelomeric and chromosome-internal heterochromatic domains collectively cover 
over 400 protein-coding genes, most of which belong to P. falciparum-specific gene families that encode virulence 
factors exported to the host erythrocyte15–18. In addition, PfHP1 also binds to a small number of euchromatic loci, 
including the gene encoding the master transcription factor of sexual differentiation PfAP2-G15,17. Consistent 
with a role for PfHP1 in heritable gene silencing, almost all PfHP1-associated genes are expressed in a clonally 
variant manner21. The best-studied example is provided by the var gene family that consists of approximately 
60 members, each encoding a variant of the erythrocyte membrane protein 1 (PfEMP1) antigen that is exposed 
on the surface of infected red blood cells (iRBCs)22–25. The PfEMP1-dependent binding of iRBCs to endothelial 
cells and uninfected RBCs leads to parasite sequestration in the microvasculature, which strongly contributes to 
severe disease26,27. Importantly, expression of the var gene family is controlled in a mutually exclusive manner 
(aka singular gene choice), such that at any given time only a single var gene is transcribed while all other family 
members are epigenetically silenced in a PfHP1-dependent manner28–31. Switches in var gene transcription then 
lead to clonal antigenic variation of PfEMP1, allowing the parasite to evade adaptive immune responses and 
establish chronic infection24,26.
Using an inducible PfHP1 loss-of-function parasite line, where PfHP1 expression levels can be modulated via 
the FKBP/DD-Shield-1 conditional expression system32,33, we recently identified three important roles for PfHP1 
in the biology of blood stage parasites31. First, we found that PfHP1 is essential for the heritable silencing of hetero-
chromatic gene families as PfHP1 depletion resulted in the de-repression of almost all var genes and many other 
subtelomeric gene families in the progeny. Second, we demonstrated that PfHP1 depletion leads to a 25-fold increase 
in sexual conversion rates, with over 50% of parasites in the progeny differentiating into gametocytes (which are 
required for malaria transmission via the mosquito vector). This striking phenotype was linked to de-repression of 
the pfap2-g locus in absence of PfHP1. Third, we showed that the remaining asexual parasites in the PfHP1-depleted 
progeny failed to enter S-phase, revealing a crucial role for PfHP1 in the control of proliferation31.
Studies in model eukaryotes have shown that HP1 is post-translationally modified, particularly by phospho-
rylation. Phosphorylation of HP1 regulates various functions in a number of cellular processes in fission yeast and 
mammals, including heterochromatic gene silencing, mitosis and DNA repair34,35. For instance, casein kinase 2 
(CK2)-dependent phosphorylation of serine residues in the N-terminal part of Swi6 is important for transcrip-
tional silencing and the recruitment of the histone deacetylase complex SHREC in S. pombe36. Similarly, in mice 
the N-terminal phosphorylation of HP1α by CK2 is important for targeting HP1 to heterochromatin as well as 
for chromosomal stability. While a single substitution of serine 14 with alanine (S14A) impaired the binding of 
HP1α to H3K9me3 and caused diffuse heterochromatic localization, multiple substitutions of clustered serines 
(S11A to S14A) hampered chromosomal integrity37. In humans, HP1 phosphorylation has been shown to play 
a role in progression through mitosis. Human HP1α is a substrate of the nuclear Dbf2-related (NDR) kinase; in 
an NDR-depleted cell line, the lack of HP1α phosphorylation at serine 95 in the hinge domain resulted in chro-
mosome alignment defects, aberrant spindle morphology and a delay in metaphase progression38. Furthermore, 
HP1 phosphorylation has also been shown to play a role the DNA damage response in humans. CK2-dependent 
phosphorylation of HP1β at threonine 51 was shown to modulate the dispersion of HP1 from chromatin, which 
in turns facilitates histone H2AX phosphorylation and recruitment of downstream regulators involved in repair-
ing chromosomal DNA breaks39.
In contrast to model eukaryotes, the functional role of HP1 phosphorylation in P. falciparum and the kinases 
involved are still unknown. Hence, to begin understanding how PfHP1 function is regulated in P. falciparum, 
we studied PfHP1 phosphorylation using in vitro and in vivo assays. Liquid chromatography tandem mass spec-
trometry (LC-MS/MS) analysis of immunoprecipitated native PfHP1 showed that PfHP1 is phosphorylated in 
its CD and hinge domains. In vitro kinase assays revealed that PfHP1 is a substrate of P. falciparum CK2 (PfCK2). 
LC-MS/MS analysis showed that PfCK2 targets three clustered serine residues within the PfHP1 hinge region in 
vitro. By generating conditional PfHP1 phosphomutant cell lines using CRISPR/Cas9-mediated genome editing 
combined with the DiCre/LoxP system40,41, we found that PfCK2-dependent phosphorylation of PfHP1, and 
phosphorylation of the PfHP1 hinge domain in general, is dispensable for proper PfHP1 localisation, gene silenc-
ing, parasite growth and sexual conversion.
Results
Identification of phosphorylated PfHP1 residues and parasite kinases phosphorylating 
PfHP1. Several large-scale phosphoproteomics studies in P. falciparum collectively detected 13 phosphorylated 
residues in PfHP1 (T2, S4, S33, T38, S57, S89, S92, S108, T110, S122, S125, S129, S174)42–47. The Y32 and S136 
residues have been identified as additional phosphosites in a recent study investigating native PfHP1 complexes48. 
To confirm and possibly expand these results, we used LC-MS/MS experiments to map phosphorylated residues 
in native PfHP1. To this end, we purified PfHP1-GFP by immunoprecipitation (IP) from nuclear extracts pre-
pared from 3D7/HP1-GFP schizont stage parasites31 in four independent biological replicate experiments (Fig. 1a). 
LC-MS/MS analysis of the eluted protein samples identified a total of eleven phosphosites in PfHP1 (Fig. 1b and 
Supplementary Table 1). One of these phosphosites (S206) has not been identified in any of the earlier studies, and 
five previously mapped phosphosites (T38, S57, S92, S108 and T110) have not been identified here (Fig. 1b). Two 
of the sites identified in our study are located in the first few residues preceding the CD domain (T2, S4), two are 
located within the CD domain in a predicted flexible loop (Y32, S33), six are located in the hinge region (S89, S122, 
S125, S129, S136, S174) and one is located in a predicted loop in the CSD domain (S206) (Fig. 1b).
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Several of the identified phosphosites conform to CK2 target sites in view of their richness in acidic residues 
(e.g. S129; SDEE), while others appear as potential targets of proline-directed kinases such as CDK, GSK3 or 
MAPK (e.g. S174; ESP), or of basic residues-directed kinases such as AGC kinases (e.g. S89; SIK) (Supplementary 
Table 1) (see Amanchy and colleagues for a comprehensive list of phosphorylation motifs49). To identify candidate 
kinases possibly phosphorylating PfHP1, we screened a set of six recombinant functional parasite kinases, namely 
PfCK250, PfGSK351, PfMAP252, PfNEK253, PfNEK454 and PfPK655, for their ability to phosphorylate recombinant 
PfHP1 in vitro, which includes the potential candidates PfCK2, PfGSK3 and PfMAP2 predicted by the phos-
phorylation site motifs outlined above. For this purpose, we used purified recombinant full-length PfHP1 and a 
truncated PfHP1 polypeptide encompassing the CD domain and hinge region (PfCD.H) (Fig. 2a). To perform 
the kinase reactions, we used an in vitro assay based on luminescence signal detection (ADP-Glo, Promega). 
Among the recombinant parasite kinases screened, PfMAP2, PfPK6, PfNEK2 and PfNEK4 showed little or no 
activity on PfHP1 (Supplementary Fig. 1). PfNEK4 phosphorylated the control substrate but not the recombinant 
PfHP1 proteins. PfMAP2, PfPK6 and PfNEK4 all displayed high autophosphorylation activities as shown previ-
ously52,53,55 and no increased consumption of ATP was observed in presence of the control substrates or PfHP1, 
suggesting that these kinases do not target PfHP1; however, we cannot exclude that low-level phosphorylation 
of PfHP1 may have been masked by the high level of autophosphorylation displayed by these three enzymes. 
PfGSK3 showed some positive enzymatic activity on PfHP1 but this result was inconclusive due to the high 
level of autophosphorylation exerted by this kinase both in the ADP-Glo assay as well as in a radioactive kinase 
activity assay employing γ-P32-ATP (Supplementary Fig. 2). Importantly, however, PfCK2 displayed remarkable 
activity in phosphorylating PfHP1 in vitro. In the ADP-Glo assay, PfCK2 showed autophosphorylation activity 
and was able to phosphorylate the control substrate β-casein. In absence of PfCK2, PfHP1 and PfCD.H exhib-
ited no signals of phosphorylation activity as expected. In contrast, when PfCK2 was added to the PfHP1 and 
PfCD.H substrates, ADP conversion increased substantially compared to PfCK2 alone or PfCK2 with β-casein 
Figure 1. Identification of phosphorylated residues in PfHP1. (a) Upper panel: silver-stained SDS-PAGE gel 
of protein samples from a PfHP1-GFP immunoprecipitation (IP) experiment using nuclear extracts from 
3D7/HP1-GFP parasites and GFP-Trap_A beads. Lower panel: Cropped section of a Western blot analysis 
of PfHP1-GFP IP samples using α-PfHP1 antibodies showing the presence of PfHP1-GFP in the input and 
elution samples. FT, flow through; W1-W5, wash 1–5; E1/E2, eluates 1 and 2. The full-size blot in shown in 
Supplementary Fig. 5. (b) Overview of all phosphosites (yellow circles) identified in PfHP1, either in this 
study by LC-MS/MS of immunopurified native PfHP1-GFP or in other proteomics studies42–48. Phosphosites 
identified here and in at least one previous study are highlighted in red letters, those identified only in previous 
studies are highlighted in black letters, and the phosphosite exclusively identified here (S206) is highlighted 
by a green letter. Helices and β-sheets predicted by the secondary structure prediction tool JPred4 (http://
www.compbio.dundee.ac.uk/jpred4/index.html)82 are indicated by orange and green boxes, respectively. The 
approximate boundaries of the CD (brown), hinge domain (grey) and CSD (pink) are indicated15. Numbers 
refer to amino acid positions in the PfHP1 sequence.
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(Fig. 2b). Consistent results were obtained for PfCK2 using the in vitro γ-P32-ATP kinase assay. PfCK2 again 
showed auto-phosphorylation activity but was clearly capable of phosphorylating β-casein as a positive control 
and, at substantially higher levels, the PfHP1 and PfCD.H substrates (Fig. 2c). The truncated PfCD.H protein was 
phosphorylated more efficiently compared to full-length PfHP1, possibly because PfCK2 may have improved 
access to the target sites in the monomeric recombinant PfCD.H protein compared to the homodimers formed by 
full-length PfHP115. To further probe the specificity of the CK2-dependent kinase reaction towards PfHP1 and 
PfCD.H, 4,5,6,7-tetrabromobenzimidazole (TBB), a selective ATP-competitive inhibitor of CK2 across species56, 
was added to the kinase reactions. The treatment with 20 µM TBB resulted in a significant drop of phospho-
rylation signal intensity in the reactions containing the substrates (Fig. 2c). Finally, to identify the residues in 
PfHP1 targeted by PfCK2 in vitro, we performed LC-MS/MS analysis of the ADP-Glo kinase assay reactions. The 
results revealed that PfCK2 phosphorylated a cluster of three serine residues in the hinge domain (S122, S125 and 
S129). Three additional predicted CK2 target residues in the PfHP1 N-terminus (T2, S4, S33; see Supplementary 
Table 1), however, where not detected in their phosphorylated form. As expected, no phosphorylated sites were 
detected in recombinant PfHP1 prior to the phosphorylation assay (Supplementary Table 2). We also failed to 
detect any phosphorylated residues in PfHP1 after incubation with PfGSK3 (Supplementary Table 2).
Overall, using three independent approaches, we demonstrate that PfHP1 is phosphorylated at least at eleven 
residues during intra-erythrocytic development, that most of these residues are located either at the N-terminus, 
in predicted loop regions in the CD and CSD domains or in the hinge domain, and that three residues in the hinge 
region (S122, S125 and S129) are phosphorylated by PfCK2 in in vitro.
Generation of conditional PfHP1 phosphomutant parasite lines. To begin addressing the in vivo 
functional significance of PfHP1 phosphorylation we concentrated on the hinge domain for three reasons. First, 
the hinge domain contains the majority of phosphorylated residues in PfHP1. Second, we identified PfCK2 as a 
kinase able to phosphorylate residues in the hinge domain in vitro. Third, the poor sequence homology between 
PfHP1 and HP1 orthologs from model eukaryotes precluded the reliable prediction of functionally important 
phosphosites in PfHP1.
To study the potential role of hinge domain phosphorylation in regulating PfHP1 function, we used two 
subsequent CRISPR-Cas9-based gene editing steps to engineer parasites that allow for the conditional expression 
of PfHP1 phosphomutants based on the DiCre-loxP system40 (Fig. 3a and Supplementary Figs 3 and 4). In the 
first step, a sera2 intron:loxP element41 was inserted into the 5′ end of the endogenous pfhp1 gene to obtain the 
3D7/N31DC mother line. PCRs on gDNA and cDNA and Sanger sequencing confirmed the correct editing of 
the pfhp1 locus and the correct splicing of the sera2 intron:loxP element (Supplementary Fig. 4). In the second 
step, a second sera2 intron:loxP element followed by a recodonised pfhp1 gene fused to gfp was placed directly 
Figure 2. PfCK2 phosphorylates PfHP1 in vitro. (a) Coomassie-stained SDS-PAGE gel showing the purified 
recombinant PfHP1 and PfCD.H proteins. (b) In vitro ADP-Glo assay results reveal that PfCK2 phosphorylates 
PfHP1 and PfCD.H in vitro. The percentage of ADP converted back into ATP (y-axis) is a surrogate measure 
for kinase activity (i.e. the relative amount of ATP consumed in the kinase reaction). β-casein was included 
as a positive control substrate for PfCK2. Recombinant PfHP1 and PfCD.H in absence of PfCK2 were used as 
negative controls. Values represent the average of two replicate reactions. Error bars represent SD. (c) Cropped 
sections of a Coomassie-stained SDS-PAGE gel (top) and the corresponding autoradiogram (bottom) of the 
in vitro γ-P32-ATP PfCK2 kinase assay performed with recombinant PfHP1 and PfCD.H substrates. β-casein 
was used as a positive control substrate. 20 µM TBB was used as a specific inhibitor of PfCK250,56. The full-size 
Coomassie-stained gel and autoradiogram are shown in Supplementary Fig. 6.
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Figure 3. Generation of DiCre-inducible PfHP1 phosphomutants. (a) Schematics of the CRISPR/Cas9-
edited pfhp1 loci (left panel) and corresponding PfHP1 protein products (right panel) expressed in the 3D7/
N31DC mother line (top) and the 3D7/HP1–3M, 3D7/HP1-HIM and 3D7/HP1-Control parasites (bottom) 
before (DMSO) and after (RAP) rapamycin-induced DiCre-dependent excision of the wild type pfhp1 locus. 
HR, homology regions used for homology-directed repair of Cas9-induced DNA double-strand breaks. 
Blue arrowheads indicate the position of sera2 intron:loxP elements41. Red asterisks indicate STOP codons. 
Blue asterisks indicate the relative position of serine-to-alanine substitutions in the PfHP1 hinge region in 
the 3D7/HP1–3M and 3D7/HP1-HIM phosphomutants. Orange and blue boxes represent the wild type 
and recodonised pfhp1/PfHP1 sequences, respectively. Numbers in the gene and protein schematics refer to 
nucleotide and amino acid positions, respectively. The black arrowheads indicate the binding sites of the F119 
and R157 primers used to confirm correct editing of the pfhp1 locus and efficient DiCre-mediated excision 
upon rapamycin treatment by PCR on gDNA (see b below). (b) PCR on gDNA confirms the correctly edited 
pfhp1 loci and efficient excision of the endogenous pfhp1 gene after rapamycin treatment in 3D7/HP1–3M, 
3D7/HP1-HIM and 3D7/HP1-Control parasites. Using primers F119 and R157 (see a) the correctly edited 
pfhp1 locus delivers a PCR product of 3781 bps in the 3D7/HP1–3M (left panel), 3D7/HP1-HIM (middle 
panel) and 3D7/HP1-Control line (right panel). In the 3D7/N31DC mother line (i.e. prior to the insertion of 
a recodonised pfhp1-gfp fusion gene) this PCR reaction delivers a 2250 bps fragment (right panel). Correct 
excision of the endogenous pfhp1 gene in rapamycin-treated 3D7/HP1–3M, 3D7/HP1-HIM and 3D7/HP1-
Control parasites results in a decrease of the size of the PCR fragment from 3781 bps to 2964 bps. Primers 
targeting the cg6 control locus (PF3D7_0709200) have been used as control. RAP, rapamycin. (c) The efficiency 
of DiCre-mediated excision of the endogenous pfhp1 gene and resulting expression of the recodonised PfHP1-
GFP fusion proteins has been quantified by counting the number of GFP-positive parasites in paired control 
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downstream of the pfhp1 STOP codon (Fig. 3a and Supplementary Fig. 3). In these parasites, activation of the 
DiCre recombinase by rapamycin is expected to excise the floxed endogenous pfhp1 gene and to place a recodon-
ised version encoding a PfHP1-GFP phosphomutant under control of the endogenous promoter (Fig. 3a). We 
generated two such conditional PfHP1 phosphomutant lines called 3D7/HP1–3M and 3D7/HP1-HIM, where 
either the three serine residues targeted by PfCK2 in vitro (S122/125/129 A) or the cluster of seven phospho-
rylated serine residues in the hinge region (S89/92/122/125/129/136/174 A), respectively, have been substituted 
by non-phoshorylatable alanines. We also generated a control cell line where rapamycin treatment results in 
the replacement of the endogenous pfhp1 with a recodonized wild type pfhp1-gfp sequence (3D7/HP1-Control) 
(Fig. 3a).
PCR on parasite genomic DNA (gDNA) was used to confirm (1) the correct integration of the recodonised 
pfhp1-gfp gene directly downstream of the endogenous pfhp1 locus; and (2) the successful DiCre-mediated exci-
sion of the floxed endogenous pfhp1 gene in schizont stages (24–36 hrs after rapamycin treatment) in all three 
cell lines (Fig. 3b). To confirm correct splicing of the sera2 intron:loxP element after rapamycin treatment and 
presence of the mutated codons encoding serine-to-alanine substitutions, RT-PCR and Sanger sequencing was 
performed (Supplementary Fig. 4). Live cell fluorescence imaging in late schizonts at 40–48 hpi (40 hrs after 
rapamycin treatment) showed that in each of the three parasite lines, excision of the endogenous pfhp1 gene 
was highly efficient and expression of the recodonised PfHP1-GFP variants was observed in close to 100% of 
parasites in the populations (Fig. 3c). In contrast, parasites in the DMSO-treated control populations did not 
express GFP-tagged PfHP1 variants as expected. Consistent with the live fluorescence imaging results, analysis of 
whole parasite protein lysates by Western Blot showed that the rapamycin-treated parasites exclusively expressed 
the recodonised PfHP1-GFP fusions, while DMSO-treated control parasites exclusively expressed wild-type 
untagged PfHP1 (Fig. 3d).
PfHP1 phosphomutants still localize to perinuclear heterochromatin. In Drosophila melanogaster 
and mice, CK2-dependent phosphorylation of HP1 is required for the correct localization of HP1 to hetero-
chromatin37,57. We therefore tested if the PfHP1 phosphomutants PfHP1–3M and PfHP1-HIM still localize to 
subtelomeric heterochromatin. Live cell fluorescence imaging in late schizonts at 40–48 hpi and in the late ring 
stage progeny at 16–24 hpi in generation 2 showed that the GFP-tagged PfHP1–3M, PfHP1-HIM and control 
PfHP1-GFP were not expressed in DMSO-treated parasites as expected. However, in the rapamycin-treated pop-
ulations the GFP-tagged PfHP1–3M and PfHP1-HIM phosphomutants were expressed and showed a punctate 
pattern at the nuclear periphery indistinguishable from that observed for the PfHP1-GFP control protein (Fig. 4). 
These results demonstrate that the phosphorylation of serine residues in the PfHP1 hinge domain is not required 
for the correct targeting and localization of PfHP1 to heterochromatin.
Phosphorylation of serine residues in the PfHP1 hinge domain is not required for parasite mul-
tiplication and plays no obvious role in regulating gene silencing. In a recent study, we showed 
that PfHP1 is required for parasite multiplication and for heritable gene silencing31. Here, we asked if phospho-
rylation of serine residues in the PfHP1 hinge domain is required for any of these crucial functions. We first 
monitored the proliferation rates of the PfHP1 phosphomutants and the control line over three consecutive gen-
erations after rapamycin treatment. As shown in Fig. 5a, in each parasite line the multiplication of DMSO- and 
rapamycin-treated parasites was highly comparable. This result indicates that phosphorylation of the PfHP1 hinge 
domain is not required for the proliferation of asexual blood stage parasites.
To identify a possible role for PfHP1 hinge domain phosphorylation in regulating pfap2-g silencing, we 
compared the sexual conversion rates between DMSO- and rapamycin-treated parasites for all three transgenic 
parasite lines. Parasite populations were split at 0–8 hpi and treated either with DMSO or rapamycin. After 
re-invasion, ring stage progeny (16–24 hpi in generation 2; day 1 of gametocytogenesis) were cultured in medium 
containing 50 mM N-acetyl-glucosamine (GlcNAc) for six consecutive days to eliminate asexual parasites58,59. 
Gametocytaemia was determined on day 6 by inspection of Giemsa-stained blood smears and sexual conversion 
rates were calculated as the fraction of gametocytaemia on day 6 in relation to the total parasitaemia observed 
on day 1. As shown in Fig. 5b, the rapamycin-treated 3D7/HP1–3M and 3D7/HP1-HIM populations showed 
significantly higher sexual conversion rates compared to the DMSO-treated populations (p < 0.01, unpaired 
two-tailed Student’s t-test). Unexpectedly, rapamycin-treated 3D7/HP1-Control parasites, which express a reco-
donised wild-type pfhp1 gene, also displayed significantly increased sexual conversion compared to the matched 
DMSO-treated population. In contrast, however, the 3D7/1G5DiCre mother line, which expresses the DiCre 
recombinase in absence of a floxed pfhp1 locus, as well as 3D7 wild type parasites did not show increased sexual 
conversion rates upon rapamycin treatment, showing that neither the rapamycin-induced expression of the DiCre 
recombinase per se nor the exposure to rapamycin affected the sexual conversion rates. Hence, the increased sex-
ual conversion rates observed for rapamycin-treated 3D7/HP1–3M, 3D7/HP1-HIM and the 3D7/HP1-Control 
(DMSO) and rapamycin-treated (RAP) populations in late schizont stages (40–48 hpi) (40 hrs after rapamycin 
treatment). Values represent the mean of three (3D7/HP1-HIM) and four (3D7/HP1–3M and 3D7/HP1-
Control) independent biological replicate experiments (>100 iRBCs scored for each population). Error bars 
indicate SD. (d) Cropped sections of a Western blot showing the expression of endogenous untagged PfHP1 and 
recodonised PfHP1-GFP in the progeny of DMSO- and rapamycin-treated 3D7/HP1–3M, 3D7/HP1-HIM and 
3D7/HP1-Control parasites (16–24 hpi, generation 2) (64 hrs after rapamycin treatment). A sample harvested 
from 3D7 wild type parasites was used as negative control sample. α-histone 4 (H4) antibodies were used as 
loading control. RAP, rapamycin. The full-size blots are shown in Supplementary Fig. 7.
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parasites rather seem to be linked to the DiCre-dependent recombination events at the floxed pfhp1 locus. 
Whatever the mechanisms underlying this puzzling observation, our data clearly suggest that phosphorylation of 
the hinge domain plays no important role in regulating pfap2-g silencing. Consistent with this result, preliminary 
experiments based on indirect immunofluorescence experiments showed similar PfEMP1 expression levels in 
DMSO- and rapamycin-treated parasites of all three lines, suggesting that hinge domain phosphorylation plays 
also no major role in PfHP1-dependent silencing of subtelomeric virulence genes.
Discussion
Heterochromatin-dependent gene silencing is an important mechanism employed by P. falciparum for clonally 
variant gene expression. PfHP1 is one of the critical factors in this process. In addition, PfHP1 is essential for 
proliferation of blood stage parasites. Phosphorylation of HP1 has been reported to dynamically regulate the 
function of this chromatin reader protein in a variety of eukaryotic organisms. Our study described here analysed 
phosphorylation of PfHP1 and its potential functional role in the biology of P. falciparum blood stage parasites.
Using immunoprecipitation of native PfHP1-GFP followed by LC-MS/MS analysis we identified eleven phos-
phorylated residues in PfHP1 purified from schizont stage parasites. All except one of these sites (S206) have 
either been identified on multiple tryptic peptides and/or in at least two of the independent IP samples analysed 
here, or they have been detected in previous studies by high-throughput phosphoproteomics approaches42–47 
and/or the mass spectrometry-based analysis of PfHP1 complexes48. Hence, we assume these residues are truly 
phosphorylated in intra-erythrocytic parasites. Five additional PfHP1 phosphosites (T38, S57, S92, S108, T110) 
that were identified in previous phosphoproteomics studies were not detected in our immunoprecipitated PfHP1 
samples. This may be explained by the fact that in contrast to these previous studies we didn’t enrich for phos-
phopeptides prior to LC-MS/MS analysis. In such raw tryptic digests the detection of phosphopeptides is often 
suppressed by the presence of the corresponding non-phosphorylated peptides. Furthermore, phosphosite 
detection by mass spectrometry is not fully comprehensive and indeed none of the previous phosphoproteomics 
studies detected all PfHP1 phosphosites simultaneously. Alternatively, it is also likely that differences in parasite 
stage composition between the samples analysed in the various studies may account for differential phosphosite 
detection.
Figure 4. Sub-nuclear localization of PfHP1 phosphomutants. Representative live cell fluorescence images 
showing the localization of the GFP-tagged PfHP1–3M and PfHP1-HIM phosphomutants and the PfHP1-
Control protein in late schizonts (LS, 40–48 hpi, generation 1; 40 hrs after rapamycin treatment) and after re-
invasion in the progeny at late ring stage (LR, 16–24 hpi, generation 2; 64 hrs after rapamycin treatment). Nuclei 
were stained with Hoechst. DIC, differential interference contrast. Scale bar, 5 µm.
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By screening a number of recombinant P. falciparum kinases using two independent kinase activity assays, 
we found that PfCK2 and PfGSK3 are able to phosphorylate PfHP1 in vitro. However, for PfGSK3 the phos-
phorylation signals obtained with the control and PfHP1 substrates were not noticeably higher compared to 
those obtained from auto-phosphorylation. GSK3 is a serine/threonine protein kinase preferring to catalyse 
substrates upon prior phosphorylation of a residue nearby the consensus sequence (S*/T*-X-X-X-S/T)60,61. 
Therefore, it is likely that GSK3 is only able to efficiently phosphorylate substrates if they have been primed by 
phosphorylation through another kinase, which was not applied in our in vitro kinase assays. Moreover, although 
PfGSK3 phosphorylated PfHP1 in the ADP-Glo assay and to some extent also in the radioactive kinase assays, no 
PfGSK3-dependent phosphosites were detected on the in vitro-reacted PfHP1 substrates by LC-MS/MS analysis. 
Hence, additional experiments with higher sensitivity will be required to confirm if PfHP1 is indeed phospho-
rylated by PfGSK3.
Importantly, however, we obtained convincing results showing that PfCK2 phosphorylates PfHP1 at a cluster 
of three serine residues located in the hinge region (LSLS122*DNS125*LKKS129*DEE), at least in vitro. Serine 
122 and S129 are embedded in a typical CK2 phosphorylation consensus target motif rich in acidic residues 
(S*/T*-D/E-X-D/E)62–64, whereas S125 lacks the favoured acidic residue at position +1 or +3 as the most crucial 
specificity determinant of the phosphoacceptor site65. However, similar atypical CK2 recognition sites contain-
ing only one acidic residue between −1 to +5 have indeed been reported66. In our efforts to analyse the role of 
PfCK2-dependent PfHP1 phosphorylation in vivo, however, we found that substituting the three target residues 
in the hinge domain with non-phosphorylatable alanines (S122/125/129A; PfHP1–3M) had no observable effect 
on PfHP1 function; parasites expressing the PfHP1–3M triple phosphomutant displayed no marked defects in 
PfHP1 localisation, pfap2-g silencing or mitotic progression. Strikingly, we even failed to observe any silencing- or 
growth-related phenotypes in parasites expressing the PfHP1-HIM phosphomutant, where seven serine residues 
in the hinge region have been replaced with alanines (S89/92/122/125/129/136/174A).
In line with these results, it has been reported that phosphorylation of S93 within the mouse HP1α hinge 
region or S89/91 within the human HP1β hinge domain does not affect HP1’s localization to chromatin37,39. In 
Figure 5. Phenotypes of PfHP1 phosphomutants. (a) Growth curves of the control (DMSO) and rapamycin-
treated (RAP) PfHP1-GFP phosphomutants and control line over three generations of intra-erythrocytic 
replication. Values are the mean of four (3D7/HP1–3M and 3D7/HP1-Control) and six (3D7/HP1-HIM) 
independent replicate experiments. Error bars represent SD. (b) Sexual conversion rates of DMSO- and 
rapamycin-treated (RAP) PfHP1-GFP phosphomutants, the PfHP1-Control line, the 3D7/1G5DiCre mother 
line and 3D7 wild type parasites. Values represent the mean of three to six independent replicate experiments. 
Error bars represent SD. Asterisks indicate significant differences in sexual conversion rates between RAP-
treated and DMSO-treated parasites (p < 0.01; unpaired two-tailed Student’s t-test).
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addition, co-immunoprecipitation of human HP1β with histone 3 revealed only a minor role for S89 phosphoryl-
ation in the ability of HP1β to bind H3K9me3, in spite of local conformational changes induced upon phospho-
rylation67. In another study on Swi6, the HP1 ortholog in S. pombe, mutations of CK2-dependent phosphosites 
in the hinge and CSD domains (S192/212/220/268/274 A) did also not affect heterochromatic gene silencing36. In 
other systems, however, essential roles of phosphorylation within the HP1 hinge region have still been reported. 
In humans, the Aurora A- and NDR1-dependent phosphorylation of serine residues in the hinge region of HP1γ 
and HP1α, respectively, both play crucial roles in mitotic progression during the G2/M phase68,69. Further, protein 
kinase A (PKA)-dependent phosphorylation of the hinge domain of a D. melanogaster HP1 variant plays impor-
tant roles in HP1 dimerisation, protein-protein interaction and binding to H3K9me370.
In conclusion, our study confirms that PfHP1 is phosphorylated during intra-erythrocytic development at 
multiple residues particularly in the CD and hinge domains. We also show that PfCK2 phosphorylates three 
clustered serine residues in the PfHP1 hinge region in vitro, but the phosphorylation of these sites is not required 
for proper PfHP1 function in blood stage parasites. If S122, S125, and S129 are indeed phosphorylated by PfCK2 
in vivo and if PfCK2 phosphorylates additional target residues in PfHP1 could be tested in future experiments 
employing conditional PfCK2 knock-down cell lines71. Surprisingly, we also demonstrate that the simultaneous 
mutation of seven phosphorylation target residues in the hinge domain has no observable effect on parasite 
viability. We therefore anticipate that phosphorylation of the PfHP1 hinge region may play an important role 
elsewhere in the parasite life cycle, for instance during meiosis in the mosquito vector and/or in the replicative 
phases during male gametogenesis, sporogony or exo-erythrocytic schizogony. While our study does not provide 
functional insight into the role of PfHP1 hinge domain phosphorylation, the experimental pipeline established in 
this study provides an elegant approach to interrogate protein function and the role of post-translational protein 
modifications in the biology of P. falciparum blood stage parasites.
Methods
parasite culture and transfection. 3D7/HP1-GFP parasites31 were cultured at 5% hematocrit in RPMI-
1640 medium supplemented with 25 mM HEPES, 100 mM hypoxanthine, 24 mM sodium bicarbonate and 0.5% 
Albumax II. The transgenic lines generated in this study were cultured in the same medium supplemented with 
2 mM choline to reduce background sexual conversion rates as demonstrated recently72. Parasite cultures were 
synchronized using 5% sorbitol as described73. Co-transfection of CRISPR/Cas9 and donor plasmids into the 
DiCre-expressing line 3D7/1G5DiCre40 and selection of transfected populations was performed as described 
recently48.
Immunoprecipitation of native PfHP1-GFP. Parasite nuclei were isolated from 30 ml culture of 3D7/
HP1-GFP early-to-late schizont stage parasites (5% hematocrit) as described previously48. Nuclear proteins were 
extracted using extraction buffer (2 M L-arginine, 1.925 M HCl, 50 mM H3PO4, and 10 mM TCEP) for 20 min on 
ice. The extract was cleared by centrifugation for 20 min at 20’000 g and 4 °C. The supernatant was diluted 1:5 with 
wash buffer 1 (WB1) (PBS containing additional 324 mM NaCl, 1 M L-proline, 1% octyl β-D-glucopyranoside 
and 2 mM TCEP) and spun again using the same conditions. Extraction buffer, WB1 and buffers used for nuclear 
isolation were supplemented with 1x protease inhibitor cocktail (Roche), 5 mM ε-aminocaproic acid (protease 
inhibitor), 3 mM sodium butyrate (histone deacetylase inhibitor) and 2 mM NaF, 2 mM β-glycerophosphate, 
4 mM sodium tartrate, 1 mM sodium pyrophosphate and 1 mM activated NaVO3 (phosphatase inhibitors). 
GFP-Trap_A beads (Chromotek) were equilibrated in WB1, added to the supernatant and rotated for 1 h at room 
temperature (RT). The beads were washed three times with WB1 and twice using WB2 (PBS containing addi-
tional 824 mM NaCl and 0.2 mM TCEP). Proteins were eluted using arginine elution buffer (2 M L-arginine, 
50 mM acetic acid and HCl to pH 4). The eluate was neutralized by addition of 0.1 volumes of 1 M tris base. Next, 
the samples were processed and analyzed using LC-MS/MS as detailed below.
Capillary liquid chromatography-tandem mass spectrometry (LC-MS/MS). For the PfHP1-GFP 
IP experiments, the neutralised elutions were reduced with 10 mM DTT at 37 °C for 1 hr and alkylated with 
50 mM iodo-acetamide for 15 min at  RT. Proteins were digested with 250 ng endoproteinase LysC (Wako, Neuss, 
Germany) for two hours at 37 °C followed by 500 ng trypsin (Worthington, Lakewood, NJ, USA) overnight. The 
digest was stopped with TFA to 1% final concentration and desalted on a microspin column (The Nest Group, 
Southborough, MA, USA) according to the manufacturer’s recommendations.
For the ADP-Glo in vitro kinase assay samples, 20 µl of the technical duplicate reactions were pooled, pre-
cipitated with 20% trichloroacetic acid (TCA) on ice for 30 min, followed by washing the precipitate with 17% 
TCA and two acetone (ice-cold) washes before air-drying the pellets. The protein pellets were dissolved in 30 μl 
100 mM Tris-HCl (pH 8.0)/6 M Urea, reduced and alkylated as above and digested with 250 ng endoproteinase 
LysC for two hours at 37 °C. The urea concentration was diluted to 2 M with 100 mM Tris-HCl (pH 8.0) and the 
sample was further digested with 500 ng trypsin overnight at 37 °C. The digest was acidified with 1% TFA and the 
sample was desalted on a MicroSpin cartridge according to the manufacturer’s recommendations.
The eluted peptides were dried in a SpeedVac and dissolved in 40 μL 0.1% formic acid and analysed by 
capillary LC-MS/MS using a home-packed separating column (0.075 mm × 25 cm) packed with Reprosil C18 
reverse-phase material (2.4 μm particle size, Dr. Maisch, Ammerbuch-Entringen, Germany). The column was 
connected on line to an Orbitrap Elite FT hybrid instrument (Thermo Scientific, Reinach, Switzerland). The 
solvents used for peptide separation were 0.1% formic acid in water (solvent A) and 0.1% formic acid and 80% 
acetonitrile in water (solvent B). 2 μl of peptide digest were injected with a Proxeon nLC capillary pump (Thermo 
Scientific) set to 0.3 μl/min. A linear gradient from 0 to 40% solvent B in solvent A in 95 min was delivered with 
the nano pump at a flow rate of 300 nl/min. After 95 min the percentage of solvent B was increased to 75% in ten 
minutes. The eluting peptides were ionized at 2.5 kV. The mass spectrometer was operated in data-dependent 
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mode. The precursor scan was done in the Orbitrap set to 60,000 resolution, while the fragment ions were mass 
analyzed in the LTQ instrument. A top twenty method was run so that the twenty most intense precursors were 
selected for fragmentation. The MS/MS spectra of the four PfHP1-GFP IP samples were searched against a 
combined P. falciparum (www.plasmoDB.org; release 9.3)/human annotated protein database using Proteome 
Discoverer 2.2 (Thermo Scientific, Reinach, Switzerland) using the two search engines Mascot and SequestHT 
(Supplementary Table 1). The PfHP1-GFP IP replicate samples 1 and 2 were additionally searched against the 
PfHP1-GFP sequence (Supplementary Table 1). The PfCK2 and PfGSK3 ADP-Glo in vitro kinase assay sam-
ples were searched against the respective PfHP1 and PfCD.H recombinant protein sequences (Supplementary 
Table 2). For the search, oxidized methionine, N-terminal protein acetylation and phosphorylation on serine, 
threonine and tyrosine were used as variable modifications. The identifications were filtered for a false discovery 
rate of 1%.
Generation of E. coli expression vectors. In order to increase the solubility strength of the SUMO tag, 
sequences encoding additional solubility tags were inserted upstream of the sequence encoding an N-terminal 
6xHis-SUMO tag as suggested elsewhere74. For this purpose, the His-SUMO-encoding sequence was PCR 
amplified from pETA-HS17 using the primers Bsa_His_f and T7term. The BsaI/XhoI-digested product was then 
cloned into BamHI/XhoI-cut pGB1 (a kind gift of S. Hiller) and pETA-MBP75, yielding the GB1-His-SUMO 
(pETA-GHS) and MBP-His-SUMO (pETA-MHS) expression vectors, respectively. Two gene fragments were 
amplified from 3D7 genomic DNA; full-length pfhp1 (using primers HP1_F and HP1_Xho_R) and a truncated 
version encoding the CD and hinge domains only (PfCD.H: M1-T181 (using primers HP1_F and CDH_Xho_R). 
XhoI-digested PCR products were ligated into SfoI/XhoI-cut expression vectors; full-length pfhp1 was cloned into 
pETA-MHS and pfcd.h into pETA-GHS. All primer sequences are listed in Supplementary Table 3.
Expression and purification of recombinant PfHP1. Both recombinant proteins were expressed in E. 
coli Rosetta2 (DE3) cells (Novagen) using auto-induction at 22 °C in ZYM-5052 medium76. Expression cultures 
were spun down at 4 °C and the pellets were kept at −20 °C. Both recombinant proteins were purified using nickel 
affinity (A), followed by dextrin affinity (MHS-HP1 only) (B) and tag removal (C). PfCD.H was further purified 
using hydrophobic interaction chromatography (HIC) (D). Both proteins were polished using gel filtration (E). 
All affinity columns used were produced by GE Healthcare. (A) Nickel affinity. E. coli pellets were resuspended 
in buffer N-A (50 mM H3PO4, 20 mM imidazole, 500 mM NaCl, 5 mM EACA and NaOH to pH 7.4) and lysed by 
sonication. The lysates were loaded on 1 ml HisTrap columns, washed with 20 column volumes (CV) of the same 
buffer and eluted using N-B (50 mM H3PO4, 225 mM imidazole, 500 mM NaCl, 5 mM EACA). For full length 
PfHP1, 2 M urea was included in the lysis buffer. The nickel eluate containing PfCD.H was buffer exchanged 
to subtraction buffer (0.75x concentrated N-A complemented with 10% glycerol, 1 mM TCEP and additional 
125 mM NaCl) using three 5 ml HiTrap desalting columns. (B) Dextrin affinity (MHS-HP1 only). The protein 
was eluted from the nickel column directly on a 5 ml MBPTrap HP column placed below the HisTrap column. 
After elution, the nickel column was removed and the MBPTrap column was washed with 5 CV of N-A and 
eluted with N-A containing 2 M urea, 10 mM maltose and 1 mM TCEP. (C) Tag removal. The GHS and MHS tags 
were cleaved off using recombinantly expressed SUMO protease (L403-K621 of S. cerevisiae ULP1; expressed 
as GB1-ULP1–6xHis fusion and purified by nickel affinity and gel filtration) in a ratio of 1:200 and incubated 
for 1.5 hours at 16 °C. In order to subtract the tag, the protease and other contaminants, the digest was passed 
through a HisTrap column. In the case of full-length PfHP1, guanine-HCl was added to a final concentration of 
1 M for this step. (D) HIC (PfCD.H only). Ammonium sulfate from a 4 M stock (pH adjusted to 7 using NH4OH) 
was added to the protein sample to 1.5 M and this mixture was loaded on a 1 ml Phenyl HP column equilibrated 
in buffer HIC (1.5 M ammonium sulfate, 5 mM EACA, 0.5 mM EDTA, 20 mM H3PO4-KOH, pH 6.8, and 10% 
Glycerol). The column was washed with 20 CV of the same buffer and the protein eluted using a 25 CV long 
linear gradient, from 1.5 M to 0 M ammonium sulfate. (E) Gel filtration. PfCD.H was polished using 10 mM 
MOPS-KOH, pH 7, 100 mM NaCl, 10% glycerol buffer and a Superdex75 10/300 GL column. For full-length 
PfHP1, a HiLoad 26/60 Superdex 200 column was prepared in three steps: first, it was equilibrated in storage 
buffer (20 mM MOPS-KOH, pH 7, 0.5 M NaCl, 10% glycerol). Then, a gradient (1/10th CV) from storage buffer 
to refolding buffer (20 mM MOPS-KOH, pH 7, 800 mM arginine, 267 mM citric acid) was loaded to the col-
umn, and finally a second gradient (1/8th CV), from refolding buffer to buffer N-A containing 2 M urea and 1 M 
guanine-HCl was loaded. As a result, the protein passed first through refolding and later through storage buffer. 
Both proteins were concentrated using Amicon spin filter (Millipore) with a 10 K cut-off and stored at −80 °C. 
Their purity and concentration were determined by SDS-PAGE and NanoDrop™ 2000/2000c spectrophotometer 
with UV extinction coefficients calculated by protparam (https://web.expasy.org/protparam/).
In vitro kinase assays. Purified recombinant P. falciparum kinases were prepared as described for PfCK250, 
PfGSK351 and PfMAP2, PfNEK2, PfNEK4, PfPK677. The ADP-Glo in vitro kinase assay was performed in dupli-
cates according to the manufacturer’s instructions (Promega, USA). In this assay, the enzymatic reaction starts 
when a kinase is added into a mixture containing the substrate and ATP. Upon completion of the reaction, the 
ADP-Glo assay quantifies the levels of ADP released from consumed ATP as a measure of kinase activity. The 
exact amount of recombinant kinase (0.6–7 μg) and PfHP1 or PfCD.H (1.8–5.8 μg) substrates used in each reac-
tion is indicated in the corresponding figures. 10 µg of either histone from calf thymus, bovine myelin basic pro-
tein (MBP) or β-casein from bovine milk (Sigma-Aldrich) were used as positive controls. 5 µl out of 25 µl of the 
kinase reactions were used for the final ATP depletion and detection steps. The remaining reaction volume was 
used for LC-MS/MS analysis to identify phosphosites (see above).
The γ-P32-ATP in vitro kinase assays were performed in a standard 25 µl reaction in kinase buffer (20 mM Tris 
HCl pH 7.5, 20 mM MgCl2, 2 mM MnCl2, 10 mM glycerolphosphate and 10 mM NaF) containing 10 µM ATP, 5 
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µCi γ-P32-ATP (3000 Ci/mmol, Amersham Biosciences), substrates (5.4 µg PfHP1, 5.8 µg PfCD.H, 10 µg β-casein, 
10 µg calf thymus histone, or 5 µg MBP) and recombinant kinases (0.5 µg PfCK2 or 0.6 µg PfGSK3). In the assay 
using PfCK2, 20 µM of 4,5,6,7-tetrabromobenzimidazole (TBB) in DMSO was use as a specific CK2 inhibitor50,56. 
The reactions were carried out for 30 min at 30 °C and stopped by the addition of Laemmli buffer. The samples 
were analyzed by SDS-polyacrylamide gel electrophoresis followed by autoradiography.
transfection constructs. We applied CRISPR/Cas9-mediated genome editing and the DiCre/LoxP sys-
tem40,41 to generate parasite lines for the conditional expression of PfHP1-GFP phosphomutants. We engineered 
(1) 3D7/N31DC_PfHP1–3M (3D7/HP1–3M) for expression of the S122/125/129A PfHP1 mutant; (2) 3D7/
N31DC_PfHP1-HIM (3D7/HP1-HIM) for expression of the S89/92/122/125/129/136/174A PfHP1 mutant; and 
(3) 3D7/N31DC_PfHP1-Control (3D7/HP1-Control) for expression of wild type PfHP1-GFP. To obtain these cell 
lines we performed two subsequent transfection steps.
In the primary transfection, we generated the mother cell line 3D7-1G5DC/5′-loxPint-g31 (3D7/N31DC), 
which carries a sera2 intron:loxP element41 inserted into the 5′ end of the pfhp1 coding sequence. To achieve 
this, we constructed the pHF-gC-guide31 plasmid by inserting two annealed complementary oligonucleo-
tides (F-g31 and R-g31) encoding the sgRNA target sequence and containing appropriate single-stranded 
overhangs into the BsaI-digested pHF-gC SpCas9 plasmid48 using T4 DNA ligase. The sgRNA target sequence 
(5′-ATTTATTTAGTAAAATGGAA-3′) is positioned at bps +70 to +89 within the pfhp1 coding sequence and 
was identified using the CHOPCHOP web tool (http://chopchop.cbu.uib.no)78,79. The donor plasmid pFdon-N31 
was generated by Gibson assembly joining four PCR fragments encoding (1) the pFdon plasmid backbone48 
digested with SalI and EcoRI; (2) the 103 bp fragment encoding the sera2 intron:loxP fragment amplified from 
pD_SIP2xGFP plasmid (I. Niederwieser, unpublished) using primers F139 and R143; (3) a 5′ homology region 
(5′ HR) spanning bps −490 upstream of the start codon to +87 in the pfhp1 coding sequence amplified from 3D7 
gDNA using primers F147 and R145; and (4) a 3′ HR spanning bps +88 to +756 of the pfhp1 coding sequence 
amplified from 3D7 gDNA using primers F146 and R144 (the pfhp1 coding sequence is 798 bps long). For 
transfection, 50 µg of each plasmid (pHF-gC-guide31 and pFdon-N31) were mixed and co-electroporated into 
DiCre-expressing 3D7/1G5DC parasites40. Transfected parasites were selected with 4 nM WR99210 for six days 
and then cultured in absence of drug selection until transgenic populations were established.
In the second step, 3D7/N31DC parasites were transfected again to generate parasite lines 3D7/HP1-3M, 
3D7/HP1-HIM and 3D7/HP1-Control that carry a second sera2 intron:loxP sequence directly down-
stream of the endogenous pfhp1 STOP codon, followed by a recodonised mutated (HP1-3M and HP1-HIM) 
or wild type (HP1-Control) pfhp1-gfp sequence using the following cloning steps. First, we constructed the 
pBF-gC-guide250 plasmid by inserting two annealed complementary oligonucleotides (F-g250 and R-g250) 
encoding the sgRNA target sequence at the 3′ end of the pfhp1 coding sequence and appropriate single-stranded 
overhangs into the BsaI-digested pBF-gC SpCas9 plasmid48 using T4 DNA ligase. The sgRNA target sequence 
(5′-AAAAAATTTAAGAGTTCCTG-3′) is positioned at bps +751 to +770 within the pfhp1 coding sequence 
(negative strand) and was identified using CHOPCHOP (http://chopchop.cbu.uib.no). Second, we constructed 
the three donor plasmids. The pD-HP1-Control plasmid was constructed by Gibson assembly joining two PCR 
fragments. The first fragment was amplified from the plasmid pD-PfHP1-KO (see Supplementary Methods) 
using primers F162 and R143 and contains, in the following order, the gpf coding sequence ending with a STOP 
codon, a 3′ HR spanning the 824 bps directly downstream of the pfhp1 STOP codon, the pD plasmid backbone72, 
a 5′ HR spanning bps +88 to +798 of the pfhp1 coding sequence carrying eight synonymous mutations between 
bps +757 to +798 (see Supplementary Methods) and ending with a STOP codon followed by the 103 bp sera2 
intron:loxP element. The second PCR fragment was amplified from a plasmid containing a synthetic recodonized 
pfhp1 sequence (pUC57-re-pfhp1) (GenScript™) (see Supplementary Fig. 3 and Supplementary Methods) using 
primers F164 and R165 and spans bps +88 to +798 of the pfhp1 coding sequence omitting the STOP codon.
The pD-HP1–3M plasmid was constructed by Gibson assembly joining four PCR fragments encoding (1) 
the 5′ HR spanning bps +88 to +798 of the pfhp1 coding sequence ending with a STOP codon followed by 
the 103 bp sera2 intron:loxP element and bps +88 to +384 of the recodonised pfhp1 sequence amplified from 
the pD-PfHP1-Control plasmid using primers F158 and R168, the latter of which introduces the S122/125A 
mutations into PfHP1; (2) a fragment spanning bps +367 to +798 of the recodonised pfhp1 sequence amplified 
from pUC57-re-pfhp1 (GenScript™) using primers F91 and R165, the former of which introduces the S125/129A 
mutations into PfHP1; (3) the gfp coding sequence ending with a STOP codon followed by the 3′ HR amplified 
from the pFdon-C-loxP-g250 vector (see Supplementary Methods) using primers F162 and R163; and (4) the pD 
plasmid backbone amplified from pUC19 using primers PCRA_F and PCRA_R72.
Finally, the pD-HP1-HIM plasmid was constructed in a two-step process. First, a fragment containing, in the 
following order, bps +88 to +798 of the recodonised pfhp1 sequence encoding the S89/92/122/125/129/136/174A 
mutations followed by the gfp sequence ending with a stop codon and the 3′ HR was generated by Gibson 
assembly joining four fragments encoding (1) bps +88 to +280 of recodonised pfhp1 amplified from 
pD-PfHP1-Control using primers F164 and R172, the latter of which introduces the S89/92A mutations; (2) bps 
+261 to +409 of the recodonised pfhp1 sequence amplified from pD-PfHP1–3M (containing the S122/125/129A 
mutations) using primers F171 and R174, the former of which introduces the S89/92A mutations and the latter of 
which introduces the S136A mutation; (3) bps +390 to +535 of the recodonised pfhp1 sequence amplified from 
pD-PfHP1-Control using primers F173 and R176, the former of which introduces the S136A mutation and the 
latter of which introduces the S174A mutation; and (4) a fragment containing, in the following order, bps +520 to 
+798 of the recodonised pfhp1 sequence, the gfp coding sequence ending with a STOP codon and 3′ HR ampli-
fied from pD-PfHP1-Control using primers F175 and R163, the former of which introduces the S174A mutation. 
Second, the resulting fragment from the first step was used as template for a second round of PCR amplification 
using primers F164 and R163 and subjected to a second Gibson assembly joining with two other PCR fragments, 
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namely the pD plasmid backbone amplified from pUC19 using primers PCRA_F and PCRA_R72, and a fragment 
containing the 5′ HR followed by the sera2 intron:loxP amplified from the pD-PfHP1-Control using primers F158 
and R143.
For each of the three transfections, 50 µg of the pBF-gC-guide250 plasmid was mixed with 50 µg of either 
pD-PfHP1-Control, pD-PfHP1–3M or pD-PfHP1-HIM and transfected by electroporation into the 3D7/N31DC 
parasite line as described above. Transfected parasites were selected with 5 µg/ml BSD-S-HCl for 10 days and then 
cultured in absence of drug pressure until transgenic populations were established. All oligonucleotide sequences 
used for the cloning of the CRISPR/Cas9 and donor plasmids are provided in Supplementary Table 3. The nucle-
otide sequence of recodonized pfhp1 is provided in Supplementary Fig. 3.
nucleic acid isolation and diagnostic pcRs and reverse transcription pcRs. To confirm correct 
editing of the pfhp1 locus we performed PCRs using the KAPA HiFi HotStart enzyme (Roche Sequencing Store) 
on gDNA isolated from the transgenic cell lines. To evaluate the excision efficiency after rapamycin treatment, 
diagnostic PCRs were performed on gDNA isolated 24–36 hours post rapamycin treatment80. To evaluate the 
splicing efficiency of the sera2 intron:loxP from the pfhp1 open reading frame, total RNA from the 3D7/N31DC 
mother cell line and the rapamycin-treated phosphomutant cell lines were isolated using Ribozol (Amresco) 
according to the manufacturer’s instruction. cDNA was then synthesized using oligo(dT) primers (RetroScript, 
Invitrogen) and PCRs on cDNA were performed using primers F106 and R107 that amplify the entire coding 
sequence. All transfection plasmids generated in this study have been validated by Sanger sequencing. All trans-
fection plasmids have been designed and Sanger sequencing results analysed using the SnapGene software (from 
GSL Biotech; available at snapgene.com). All primer sequences used for PCR are listed in Supplementary Table 3.
Induction of DiCre recombinase-mediated DNA excision by rapamycin treatment. Parasites 
were synchronized twice 16 hours apart to obtain an eight-hour growth window (16–24 hpi). After re-invasion 
parasites were synchronized again at 0–8 hpi (generation 1) and split into two equal populations, one of which 
was treated with 0.02% v/v of DMSO (negative control) and the other half was treated with 100 nM rapamycin 
for 1 hour80. The cultures were then spun down, washed with an equal volume of culture medium, resuspended in 
culture medium and returned to culture.
SDS-PAGE and immunoblotting. After DMSO or rapamycin treatment in generation 1, parasites were 
allowed to complete schizogony and re-invasion. At 16–24 hpi in generation 2, parasites were released from 
iRBCs by 0.15% saponin/PBS complemented with 1X protease inhibitor (Roche Diagnostics). After washing 
2–3 times in ice-cold PBS, parasite pellets were lysed in 70 °C pre-heated Urea/SDS buffer (8 M Urea, 5% SDS, 
50 mM Bis-Tris, 2 mM EDTA, 25 mM HCl at pH 6.5 supplemented with 2 mM DTT and 1X protease inhibi-
tor). Whole parasite protein lysates were separated on NuPage 4–12% Bis-Tris gels (Novex) and analyzed by 
Western blot using mouse mAb α-GFP (Roche Diagnostics #11814460001), 1:1000; rabbit α-PfHP131, 1:5’000; 
rabbit α-Histone 4 (Abcam ab10158), 1:10’000. The blot shown in Fig. 3d was first probed with α-GFP antibodies, 
stripped in 2% SDS, 62.5 mM Tris-HCl (pH 6.8), 100 mM β-mercaptoethanol for 30 min at 60 °C, and re-probed 
with rabbit α-PfHP1 and α-Histone 4 antibodies simultaneously.
Live cell fluorescence imaging. To quantify the efficiency of pfhp1 excision after rapamycin treatment, 
live cell fluorescence microscopy was performed as described before81 with minor modifications using Hoechst 
(Merck) at a final concentration of 5 µg/ml to stain the nuclei. Excision efficiency was determined as the percent-
age of GFP-positive schizonts at 40–48 hpi in generation 1 (>100 schizonts counted per experiment). Images 
were taken at 63-fold magnification on a Leica DM 5000B microscope with a Leica DFC 300 FX camera, acquired 
via the Leica IM 1000 software, processed using ImageJ software (https://imagej.nih.gov/ij). For each experiment, 
images were acquired and processed with identical settings.
parasite multiplication assay. Parasites were tightly synchronized twice 16 hours apart, split into two 
equal populations after re-invasion at 0–8 hpi (generation 1), of which one half was treated with DMSO (negative 
control) and the other half was induced for DiCre recombinase-mediated DNA excision by rapamycin treatment 
as described above. Giemsa smears were prepared to determine the parasitaemia at 16–24 hpi (generation 1). 
Giemsa-stained smears were prepared every second day onwards for three generations. Parasitaemia was counted 
by visual inspection of Giemsa-stained blood smears (>3′000 RBCs counted per experiment). Multiplication 
rates were determined as the parasitaemia observed in the following generation divided by the parasitaemia 
observed in the previous generation.
Gametocyte conversion assay. Parasites were tightly synchronized twice 16 hours apart and split into two 
equal populations after re-invasion at 0–8hpi (generation 1), of which one half was treated with DMSO (negative 
control) and the other half was induced for DiCre recombinase-mediated DNA excision by rapamycin treat-
ment as described above. At 16–24 hpi in the subsequent generation (day 1 of gametocytogenesis), cultures were 
treated with 50 mM N-acetyl-D-glucosamine (GlcNAc) for six days to eliminate asexual parasites58,59 and then 
cultured with normal culture medium for another 4–6 days to observe gametocyte maturation. Gametocytaemia 
was determined on day 6 by visual inspection of Giemsa-stained blood smears. Sexual conversion rates were 
determined as the gametocytaemia observed on day 6 as a proportion of the total parasitaemia observed on day 1.
Data availability
All data generated or analysed during this study are included in this published article (and its Supplementary 
Information files).
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